Elie Helou
Internal Medicine · Waterbury, CTNPI 1912252115
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Gilead at 52.2% of the total. 2025 is the largest year on record at $31,781, 7.1 times the $4,495 reported in 2019. Among internal medicine clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,225 payments — averaging $65.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$42K
- Merck$13K
- Viiv Healthcare Company$6K
- Theratechnologies Inc.$3K
- AbbVie$3K
- Amgen$2K
- plus $11K from 41 others
Across 2 payments — averaging $51,678 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Theratechnologies Inc.$103K
What the payments were for
- Consulting fees$2,0503%
- Speaking & faculty fees$45,26556%
- Travel & lodging$1,5222%
- Food & beverage$30,96139%
- Education$6031%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$80,401 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 100 | $421,633 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 54 | $191,393 |
| JulucaDolutegravir/Rilpivirine | 45 | $155,884 |
| TrogarzoIbalizumab-Uiyk | 13 | $150,560 |
| CabenuvaCabotegravir/Rilpivirine | 21 | $145,531 |
| DescovyEmtricitabine/Tenofov Alafenam | 57 | $125,951 |
| Egrifta SvTesamorelin Acetate | 14 | $97,104 |
| JardianceEmpagliflozin | 101 | $93,514 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 15 | $89,173 |
| TradjentaLinagliptin | 103 | $88,720 |
| OzempicSemaglutide | 61 | $77,475 |
| DovatoDolutegravir Sodium/Lamivudine | 23 | $67,862 |
| LinzessLinaclotide | 94 | $64,831 |
| PifeltroDoravirine | 33 | $54,791 |
| RybelsusSemaglutide | 48 | $51,705 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $41,985 | $594,593169 claims |
| Viiv Healthcare CompanyTriumeq, Juluca, Cabenuva, Dovato | $6,026 | $560,670143 claims |
| Theratechnologies Inc.Trogarzo, Egrifta Sv | $2,839 | $247,66427 claims |
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto, Spiriva Respimat, Stiolto Respimat | $1,442 | $215,271254 claims |
| MerckPifeltro, Januvia, Isentress Hd, Janumet, Janumet Xr | $13,250 | $180,601142 claims |
| Novo NordiskOzempic, Rybelsus | $427 | $129,180109 claims |
| AbbVieLinzess | $2,598 | $64,83194 claims |
| Johnson & JohnsonPrezcobix | $1,496 | $50,04322 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,899 | $29,59133 claims |
| Lilly USA, LLCMounjaro, Trulicity | $554 | $27,60727 claims |
| AmgenProlia | $2,335 | $22,75013 claims |
| PfizerEliquis | $1,303 | $19,33733 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Waterbury
- Joseph PrunerWaterbury$19K
- David DeluciaWaterbury$17K
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$1.6M
- Arthur DecillisMadison$1M
- Charles MontanoCromwell$970K
- Gary BlickNorwalk$683K
- Scott GottliebStamford$508K
- Jeffrey KatzOxford$361K
- Nicholas DainiakBridgeport$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.